Anti-interleukin-12 antibody for active Crohn's disease.

By P. Mannon, I. Fuss, L. Mayer, C. Elson, W. Sandborn, D. Present, B. Dolin, Nancy Goodman, C. Groden, R. Hornung and 7 more. New England Journal of Medicine, 2004

801 citations recorded by the source corpus.

Subfields: Genetics, Immunology, Rheumatology

View Paper: https://www.semanticscholar.org/paper/4fa7e09dd16916c1be432e1f75e12c5cbc749470

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Genetics

1. F. Powrie
2. K. Maloy
3. D. Artis
4. Judy H. Cho
5. Bruce E. Sands
6. C. A. Dinarello
7. R. Sartor
8. B. Feagan

In Immunology

1. D. Cua
2. C. Weaver
3. Christopher A. Hunter
4. L. Harrington
5. Paul R. Mangan
6. D. Artis
7. R. Kastelein
8. F. Powrie

In Rheumatology

1. C. A. Dinarello

Citations in the corpus

• Secukinumab, a human anti-IL-17A monoclonal antibody, for moderate to severe Crohn’s disease: unexpected results of a randomised, double-blind placebo-controlled trial (2012, background): “Phase II trials in Crohn’s disease have reported that blockade of p40, the shared subunit of the T helper cell 1 (Th1) cytokine IL-12 and the Th17 modulator IL-23, is effective.(17) 18 Although anti-p40 antibodies were assumed to abrogate interferon g mediated intestinal inflammation through blockad”
• Mechanisms of Disease: pathogenesis of Crohn's disease and ulcerative colitis (2006, background): “Antibody-neutralization studies have implicated tumor necrosis factor (TNF) and IL-12 p40 in the pathogenesis of Crohn's disease”
• The IL-23/Th17 axis in the immunopathogenesis of psoriasis. (2009, background): “Indeed, clinical data from phase II studies on anti-IL-12p40 in CD further support IL-12p40 as an appropriate target for CD therapy (Mannon et al., 2004).”
• New IL-12-family members: IL-23 and IL-27, cytokines with divergent functions (2005, methodology): “This is illustrated by a Phase 2 clinical trial in which administration of an IL-12p40-specific human monoclonal antibody resulted in reduced clinical disease, and this was associated with improved histology of mucosal tissues and decreased production of cytokines by mononuclear cells that were isol”
• Border patrol: regulation of immunity, inflammation and tissue homeostasis at barrier surfaces by IL-22 (2011, background): “Indeed, inhibiting the activity of IL-23 and IL-12 with a monoclonal antibody that binds the common p40 subunit of these cytokines has demonstrated beneficial outcomes in the treatment of Crohn's disease and psoriasi”
• IL-23 is essential for T cell-mediated colitis and promotes inflammation via IL-17 and IL-6. (2006, background): “In vivo administration of mAbs.”
• Discovery and biology of IL-23 and IL-27: related but functionally distinct regulators of inflammation. (2007, methodology): “This is illustrated by clinical trials in which administration of a p40-specific human monoclonal antibody resulted in reduced clinical disease, associated with improved mucosal histology and decreased production of cytokines by mononuclear cells isolated from the lamina propria (85, 86).”